triciribine has been researched along with 2019 Novel Coronavirus Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bi, Y; Chen, W; Hu, W; Li, J; Liu, J; Shi, D; Xiang, Z; Yan, R; Yang, Z; Yu, Y; Zhu, Z | 1 |
| Adil, MS; Narayanan, SP; Rudraraju, M; Somanath, PR; Verma, A | 1 |
2 other study(ies) available for triciribine and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Glucocorticoids improve severe or critical COVID-19 by activating ACE2 and reducing IL-6 levels.
Topics: Adenosine; Adult; Aged; Angiotensin-Converting Enzyme 2; Antiviral Agents; Betacoronavirus; Cell Line; Cell Line, Tumor; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokines; Epithelial Cells; Female; Gene Expression Regulation, Neoplastic; Glucocorticoids; Humans; Hydrocortisone; Interleukin-6; Kinetin; Macrophages; Male; Middle Aged; Monocytes; Pandemics; Peptidyl-Dipeptidase A; Pneumonia, Viral; Retrospective Studies; Ribonucleosides; SARS-CoV-2; Transcriptome | 2020 |
Akt-independent effects of triciribine on ACE2 expression in human lung epithelial cells: Potential benefits in restricting SARS-CoV2 infection.
Topics: A549 Cells; Angiotensin-Converting Enzyme 2; Bronchi; COVID-19; COVID-19 Drug Treatment; Epithelial Cells; Gene Expression Regulation; HMGB1 Protein; Humans; Lung; Proto-Oncogene Proteins c-akt; Ribonucleosides; RNA, Viral; SARS-CoV-2 | 2021 |